AGMBAgomab Therapeutics NVvs its industry peers
A metric-by-metric comparison of Agomab Therapeutics NV against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGMBEsta | $234M#2 | — | — | — | — | — | — | — | — | — | — | — |
| TVGNW | $526132#4 | — | — | — | — | -91.4%#8 | — | — | — | — | 86.2%#2 | — |
| SCLXW | $356706#5 | — | — | 0.0x#1 | -46.5%#6 | -413.8%#9 | -1143.7%#4 | — | — | 4#1 | 382.5%#1 | — |
| ABPWW | $116152#6 | 0.0x#2 | — | 0.6x#3 | 50.0%#2 | 60.0%#3 | -4618.6%#5 | — | — | — | -19.3%#4 | — |
| SLXNW | $99529#7 | 0.0x#1 | 2.3x#1 | — | — | 27.9%#6 | — | -27072.7%#1 | — | — | — | — |
| ABPO | — | — | — | — | 50.0%#2 | 60.0%#3 | -4618.6%#5 | — | — | — | — | — |
| ADAPY | — | — | — | — | 195.3%#1 | 37.8%#5 | -38.6%#3 | — | — | — | — | — |
| AGTX | — | — | — | — | -100.0%#7 | 14.4%#7 | — | — | — | — | — | — |
| ALVO | $1.5B#1 | — | — | 2.5x#4 | 19.7%#4 | 112.0%#1 | 13.3%#1 | — | — | — | -3.1%#3 | — |
| ALVOW | $144M#3 | — | — | 0.2x#2 | 19.7%#4 | 112.0%#1 | 13.3%#1 | — | — | — | -60.0%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-05.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice